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Abstract
Aim—Genetic polymorphisms have the potential to influence drug metabolism and vary among
ethnic groups. This study evaluated the correlation of genetic polymorphisms with nevirapine
pharmacokinetics exposure in Malawians.
Materials & methods—CYP450 2B6, 2D6, 3A4 and 3A5, ABCB1 and constitutive androstane
receptor and pregnane X receptor, were analyzed for polymorphisms in 26 subjects.
Results—Allele frequencies (variant) were: CYP2B6 514G>T (0.31) CYP2D6*4 (0.02);
CYP2D6*17 (0.35); CYP3A4*1B (0.77); CYP3A5*3 (0.25); ABCB1 2677G>T (0.0), ABCB1
3435C>T (0.21), NR1I3 13711152T>C (0.02), NR1I2 44477T>C (0.10), NR1I2 63396C>T (0.33),
NR1I2 6-bp indel (del: 0.17). CYP2B6 516G>T (non-wild-type/wild-type) correlated with
nevirapine pharmacokinetic parameters; geometric mean ratios (95% CI): 1.75 (1.27–2.40) for
area under the concentration time curve (AUC)0–12 h, 1.58 (1.03–2.42) for C0, and 0.53 (0.31–
0.91) for clearance. In a multivariable model, nevirapine AUC increased by 1.5% per year of age
(p < 0.0001), CYP2B6 516 T allele increased AUC by 92% (p < 0.0001), and CYP3A5*3
decreased AUC by 31% (p = 0.0027).
Conclusion—Allele frequencies were similar to other sub-Saharan African populations. The T
allele for CYP2B6 516 was significantly associated with nevirapine exposure.
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Genetic polymorphisms have been identified in genes that encode drug-metabolizing
enzymes and transporters such as the CYP450s (CYPs; CYPs) and P-glycoproteins (MDR1;
ABCB1) [1]. These polymorphisms may explain interindividual differences in drug
pharmacokinetics [1]. Patients with genotypes that produce less active enzymes in major
drug metabolic pathways have reduced metabolism and therefore higher drug exposures and
potentially more adverse effects. Patients with activity-enhancing genotypes clear drugs
faster, which can lead to subtherapeutic concentrations and increased risk of therapy failure
[1]. Specifically, CYP polymorphisms have been associated with interpatient variation in
antiretroviral plasma concentrations, and the allele frequencies vary among ethnic groups
[2,3].
HIV-infected patients on antiretroviral therapy have demonstrated altered plasma
concentrations due to differing CYP450 enzyme genotypes [2,4,5]. These genotypes have
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also shown differing frequencies based on ethnicity [6]. A Ugandan population has been
shown to have significantly higher drug exposure compared to western populations; this can
partially be explained by different frequencies of genetic polymorphisms in drug-
metabolizing enzymes and transporters [7].
Antiviral therapy is expanding in developing countries using doses optimized for western
populations. We recently found that steady-state nevirapine concentrations were
significantly increased in a group of Malawian adults and children compared to
concentrations seen in a mostly western Caucasian cohort of adults and children [8–11]. The
1.6- to 2.2-fold increase in drug exposure could not be explained by weight, age or other
observable patient-specific factors. Nevirapine is non-nucleoside reverse transcriptase
inhibitor used for the treatment of HIV infections in adults and children. It is metabolized by
the CYP450 system, specifically CYP3A4/5, CYP2D6 and CYP2B6 [12], and data suggest
that polymorphisms in the genes encoding these enzymes can alter nevirapine concentrations
[2,7,13–18]. The clinical impact of the CYP2B6 polymorphism, 516G>T, has been described
in various settings. The use of single-dose nevirapine to prevent perinatal vertical
transmission has been shown to have prolonged exposures in women with the CYP2B6 516
T allele, which greatly increases the risk of developing non-nucleoside reverse transcriptase
inhibitor resistance mutations [18].
Nevirapine autoinduces its metabolism by activating CYP3A4/5 and CYP2B6 expression,
and data show that nevirapine may do this through the activation of the nuclear receptor,
constitutive androstane receptor (CAR; NR1I3) [19]. The nuclear receptor pregnane X
receptor (PXR; NR1I2) regulates basal expression of CYP3A4/5 [20]. Polymorphisms in the
genes coding for these nuclear receptors have been shown to influence the expression of the
CYPs and therefore influence nevirapine exposure [19–21].
Frequencies of polymorphisms in CYP3A4/5, CYP2B6, ABCB1, PXR and CAR can vary
between ethnic groups [22], which might contribute to the difference in drug exposure we
previously observed between Malawians and western subjects [2,8,9]. However, the




This was a nonrandomized pharmacogenetic observational study in HIV-infected Malawian
children and adults who participated in pharmacokinetic studies evaluating nevirapine [8,9].
The University of North Carolina Institutional Review Board and the Malawi National
Health Sciences Research Committee approved the study protocol. All research subjects
provided consent or assent with guardian consent. The objective was to determine the
frequencies of CYP, ABCB1 and nuclear receptor polymorphisms in 30 Malawian adults and
children and to explore correlations between their genotypes and nevirapine (Virammune®)
exposure.
Samples & DNA extraction
Nevirapine concentrations were measured in blood plasma by a validated HPLC-UV method
as previously described [8,9,23].
DNA was isolated from whole blood using the QIAamp® DNA Mini kit (Qiagen Sciences,
MD, USA). Genotyping was performed using PCR and Pyrosequencing® as previously
described [24]. Primers and PCR conditions for ABCB1 2677 (rs2032582) and 3435
(rs1045642), CYP2B6 516G>T (Q172H; rs3745274), CYP2D6*4 (rs3892097), CYP3A4*1B
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(rs2740574), and CYP3A5*3 (rs776746) were previously described [24–27]. For
CYP2D6*17 (rs28371706), DNA was amplified using the forward primer: 5′-GAG GCG
CTG GTG ACC CAC-3′ and biotinylated reverse primers: 5′-biotin-CTG TCC CCA CCG
CTG CTT-3′ at an annealing temperature of 65°C. The internal primer was 5′-CGC CTG
TGC CCA TCA-3′ and the sequence to analyze was C/TCCAGATCC.
NR1I2 44477T>C (rs1523130), 63396C>T (rs2472677) and the 6-bp deletion (6-bp indel;
rs3842689) were genotyped by previously described methods [20]. The trans NR1I3
polymorphism, rs10494390 (NT_004487.18:g.13711152T>C), was amplified from 50 ng of
genomic DNA by the forward 5′-ACCTTCGGGGTTGAATTTT-3′ and reverse 5′-
TGTAGCATTTGGGTTTTGGA-3′ primers.
Data analysis/statistics
Genotype data from the Malawi sample was compared to genotype data of Yoruban (sub-
Saharan African), African–American and Caucasians of European descent obtained from the
HapMap database. Fisher’s Exact Test was used to determine whether the Malawian
sample’s genotype frequencies differed significantly from the archived data. The Cochran–
Armitage Trend Test was employed to determine if a genotype trend could be detected
between groups.
The pharmacokinetic parameters were generated by noncompartmental analysis using
WinNonlin (v5.2, Pharsight, Inc., NC, USA). Area under the concentration time curve
(AUC) 0–12 h was extrapolated from partial dosing interval data (adults: 0–8 h, children: 0–6
h). Weight-adjusted (kg) apparent oral clearance (CL/F) was determined to confirm AUC
results of the pediatric subjects. Trough concentrations (C0) are predose concentrations.
Statistical analysis was performed using SAS (v9.1.3, SAS Institute, NC, USA). Geometric
mean ratios (GMRs) of non-wild-type (WT) versus WT genotypes were calculated using
linear regression of natural log transformed pharmacokinetic parameters with α significance
levels of 5% and 0.625%; the latter to account for multiple statistical tests for the eight
genotypes tested. Multiple linear regression was performed to develop a multiple variable
model (α = 0.05) with AUC as outcome and genotypes and demographics as covariates. WT
genotypes are defined as genotypes that are homozygous for the WT allele, and non-WT
genotypes are defined as genotypes that are either heterozygous or homozygous for the
variant (VAR) allele. WT alleles are defined by having functional enzyme gene products,
often designated as *1 for the CYPs, or having the highest allele frequency in this study
sample.
Results
DNA was isolated from 24 Malawian subjects, of whom 11 were adults with a median
(range) age of 40 (26–46) years, weight of 72 (60–80) kg, BMI of 25.4 (19.8–32.5) kg/m2
and five were male. Thirteen were children with median (range) age of 6.7 (1.3–13.6) years,
weight of 18 (9–30.5) kg, BMI z-score of 0.31 (−5.39–1.28) and six were male [8,9].
Subjects were also taking trade formulations of lamivudine (Epivir®) and stavudine (Zerit®)
at the time of pharmacokinetic sampling. Nevirapine was dosed using standard dosing in
adults at 200 mg twice daily. The pediatric group was dosed using standard weight-based
dosing, in which children up to 8 years of age are dosed 7 mg/kg twice daily and children 8
years of age and older are dose 4 mg/kg twice daily.
Genotype frequencies of 26 Malawians are presented in Table 1; genetic sampling included
two subjects without pharmacokinetic data. The genotypes could not be reliably tested for
Hardy–Weinberg equilibrium due to a small sample size. The Malawian genotype
frequencies did not differ from Yorubans. The Malawian’s CYP2D6*17 and ABCB1
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2677G>T genotype data differed from that of the African–American individuals; other
genotypes tested did not differ. The Malawian genotype frequencies differed from
Caucasians in regards to all genotypes tested except for CYP2B6 516G>T (p = 0.31). The
VAR allele frequencies of CYP3A4*1B and CYP2D6*17 were higher and CYP3A5*3,
CYP2D6*4, ABCB1 2677G>T, ABCB1 3435C>T, NR1I3 13711152T>C, NR1I2 44477T>C,
63396C>T and 6-bp indel were lower in the Malawians than Caucasians.
The results of the correlation analysis are listed in Table 2. The pharmacokinetic data were
log normally distributed. With α = 0.05, the CYP2B6 516 T allele was significantly
associated with increased AUC, C0 and CL/F. With α = 0.00625 for multiple comparison
correction, this significance was lost . The NR1I2 6-bp indel deletion allele was significantly
associated with decreased AUC0–12 h and increased CL/F with α = 0.05; however, this lost
significance with α = 0.00625.
Figure 1 shows a decrease in weight-based CL/F with the number of CYP2D6*17 alleles
within the pediatric group. This was not seen in the adult subjects (Figure 1b). In order to
confirm the effect of CYP2D6*17 on CL/F in the pediatric group, the GMR for CL/F was
determined separately in the pediatric and adult groups. The GMR (VAR/WT; 95% CI) for
CYP2D6*17 was 0.59 (0.36–0.98; p = 0.04) and 1.02 (0.61–1.70; p = 0.9) for children and
adults, respectively, demonstrating that CYP2D6*17 is associated with decreased clearance
only in the pediatric group of our sample.
The following multiple variable model was determined for nevirapine AUC: Ln(AUC0–12 h)
= 10.67 + 0.65 (2B6Var) – 0.37 (3A5Var) + 0.015 (age). The CYP2B6 516 T allele increases
AUC0–12 h by 92% (95% CI: 51–145%), CYP3A5*3 allele decreases AUC0–12 h by 31%
(95% CI: 12–46%) and age increases AUC0–12 h by 1.5% (95% CI: 0.7–2%) per year. Table
3 shows the p-values for each of the variables tested. The effect of the PXR 6-bp indel on
nevirapine AUC was not significant in the final multiple variable model despite significance
(α = 0.05) seen in the univariate analysis. A similar model was determined for weight-
adjusted CL/F (not shown).
Discussion
CYP2B6 genotype is associated with intra-population differences in Malawians. Consistent
with previous studies [7], the T allele at CYP2B6 516 correlated with increased exposure and
decreased clearance of nevirapine. Since our study and others have demonstrated association
of the T allele with increased nevirapine exposures and varying frequencies of CYP
polymorphisms among ethnic groups, antiretrovirals must be evaluated in all potential
treatment populations [2,7].
Drug-metabolizing enzyme and transporter genotype data from our sample agree with other
African populations as reported in the HapMap database (Luhya in Webuye, Kenya; Maasai
in Kinyawa, Kenya and the Yoruban in Ibadan, Nigeria) [22]. For example, CYP2B6 516 T
allele frequencies ranged from 0.315 to 0.42 for the African groups in the HapMap database;
the Malawian frequency was 0.31. For CYP3A5*3, the HapMap database reports a wide
range of allele frequencies: 0.128–0.486 (Malawians frequency: 0.25), which demonstrates
sub-Saharan African ethnic groups could have dissimilar CYP allele frequencies. This may
be clinically relevant to drugs metabolized by these CYP enzymes.
Following the multiple comparisons correction, CYP2B6 516 T allele correlated with
increased AUC. CYP2B6 and age were independently associated with nevirapine AUC, C0
and CL/F. CYP3A5*3 is an allele that causes decreased function of CYP3A5 and is expected
to decrease clearance of nevirapine, thereby increasing its exposure. Although there was no
correlation in the univariate analysis, CYP3A5*3 was associated with decreased AUC when
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controlling for CYP2B6 and age. CYP3A5*3 correlating with lower nevirapine exposure
may be a result of heterozygous individuals in our sample expressing more enzyme than
homozygous WT individuals and/or CYP3A5*3 being in linkage with another functional
allele [28]. In addition, our sample did not include individuals who were CYP3A5*3/*3,
which is a genotype found only in Africans based on the HapMap data, which may introduce
bias in our model.
The CYP2D6*17 allele appears to be specific to African populations and is associated with
decreased CYP2D6 enzyme activity [3]. Only within the pediatric group did CYP2D6*17
correlate with a decrease in weight-adjusted nevirapine CL/F, suggesting that CYP2D6 may
play a larger role in nevirapine metabolism in children. However, this would need to be
confirmed in a larger study population accounting for other CYP2D6 SNPs and other
polymorphisms in linkage disequilibrium.
CAR and PXR are functionally linked with the expression of various CYPs [19]. Nevirapine
preferentially induces CYP2B6 through activation of CAR [19], and polymorphisms in PXR
are associated with higher basal expression and reduced induction of CYP3A4 activity [20].
Polymorphisms in NR1I3 and NR1I2 may attenuate the induction of CYP2B6 and CYP3A5
leading to higher nevirapine exposures; however, our study did not demonstrate this. The
NR1I2 6-bp indel, which is in linkage disequilibrium with NR1I2 44477T>C, was associated
with lower nevirapine exposures, which may indicate increased basal expression of
CYP3A4.
The multivariable model showed that nevi-rapine concentrations were influenced by
CYP2B6 and CYP3A5 genotypes in addition to age. Currently there is limited clinical utility
for this model, due to a lack of widely available genotypic testing for these enzymes in all
populations. In addition, there is limited data linking genotype, concentration and safety and/
or efficacy. Despite this, the clinical implications of this model include that it is possible to
predict nevirapine exposures based on genotype. With more advanced modeling methods,
nevi-rapine concentrations could be predicted based on genotype and other known patient
factors in order to predict adverse effects such as rash due to supratherapeutic concentrations
or virologic failure due to subtherapeutic concentrations. However, these models will also be
limited to the groups in which they are studied. In addition, this is a potentially useful tool
for research purposes in which outliers of drug concentrations exist with no obvious
decreased adherence or extra dosing.
The US Department of Health and Human Services (US DHHS) currently recommends a
target nevirapine trough plasma concentration of 3 μg/ml based on data demonstrating a
five-fold increase in virologic failure risk with lower trough concentrations [29,30,101].
These data were developed in a Caucasian population with the same doses currently being
used in African populations. The Malawian and other sub-Saharan African HIV-infected
patients would benefit greatly from efficacy and safety studies focusing on their populations
since there is an overwhelming amount of data demonstrating that these groups have genetic
differences that affect how the drugs are metabolized and eliminated.
Factors such as nutritional status and diet can also affect drug metabolism. Low protein and
high carbohydrate consumption are associated with decreased hepatic CYP metabolism,
while high protein diets are associated with increased metabolism [31]. Our subjects had
normal nutritional status based on BMI, except for one underweight child. Western diets are
generally higher in animal protein than those in sub-Saharan Africa, while diets in Malawi
are considerably lower in animal protein and include carbohydrate-rich protein sources
[102]. This dietary factor may contribute to the differences observed in nevirapine exposure
between Malawians and westerners.
Brown et al. Page 6













Despite our limited sample size, our novel pilot data provide evidence that ethnic diversity
of drug-metabolizing enzyme genetics may play a role in antiretroviral drug exposures.
Larger studies are needed to define population allele frequencies and to evaluate the clinical
impact of drug-metabolizing enzymes, transporter and nuclear receptor polymorphisms.
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Nevirapine pharmacokinetics in Malawians
• Previously studied HIV-infected adults and children had 1.6- to 2-fold higher
exposures compared to published data in western cohorts.
• Drug exposures can be influenced by polymorphisms in genes encoding
enzymes, transporters and receptors that are involved in drug metabolism and
elimination.
Aim
• We sought to identify the allele frequencies of known genetic polymorphisms in
drug-metabolizing enzymes, transporters and nuclear receptor genes in
Malawians and evaluate the influence of these genetic polymorphisms on
nevirapine pharmacokinetics.
Allele frequency & genotype correlation with nevirapine pharmacokinetics
• Malawian allele frequencies were similar to other sub-Saharan Africans, but
differed from Caucasians.
• The CYP2B6 516 T allele was significantly correlated with increased nevirapine
exposures.
• CYP2D6*17 was associated with increased clearance only in children.
• In a multivariable model, nevirapine AUC increased by 1.5% with each year
increase in age, increased by 92% with the presence of the CYP2B6 516 T allele
and decreased by 31% with the presence of CYP3A5*3.
Conclusion
• Genetic polymorphisms influence nevirapine metabolism in Malawians.
• Larger studies are needed to evaluate the clinical impact of genetic variability
among ethnic groups.
Brown et al. Page 10













Figure 1. Weight-adjusted clearance versus CYP2D6*17 genotype (*17 = T allele) in the pediatric
group and adult group
(A) Pediatric group, (B) Adult group.
CL: Clearance.
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Table 2
Pharmacokinetic parameter geometric mean ratios (non-wild-type or variant versus wild-type).
Polymorphism NVP AUC0–12 h NVP AUC0–6 h† NVP C0 CL/F‡
CYP2B6 516G>T 1.75* 1.71* 1.58** 0.53**
rs3745274 (1.27–2.40) (1.25–2.34) (1.03–2.42) (0.31–0.91)
CYP3A4*1B§ 0.86 0.87 0.87 0.96
rs2740574 (0.59–1.27) (0.60–1.27) (0.55–1.39) (0.53–1.74)
CYP3A5*3 0.91 0.92 0.93 1.03
rs776746 (0.62–1.33) (0.63–1.35) (0.59–1.48) (0.57–1.86)
CYP2D6*17 1.13 1.11 1.06 0.94
rs28371706 (0.76–1.68) (0.75–1.64) (0.65–1.70) (0.51–1.72)
ABCB1 3435C>T 1.10 1.07 0.98 0.83
rs1045642 (0.75–1.63) (0.73–1.58) (0.61–1.57) (0.46–1.50)
NR1I2 44477T>C 0.80 0.81 0.90 1.21
rs1523130 (0.50–1.28) (0.51–1.27) (0.51–1.59) (0.58–2.49)
NR1I2 63396C>T 0.80 0.79 0.82 1.35
rs2472677 (0.55–1.17) (0.55–1.14) (0.52–1.30) (0.76–2.42)
NR1I2 6-bp indel 0.67** 0.71 0.66 1.86**
rs3842689 (0.45–0.999) (0.48–1.05) (0.41–1.07) (1.02–3.39)
The geometric mean ratios (95% CI) for nevirapine AUC0–12 h, AUC0–6 h, C0 and CL/F comparing data from subjects (n = 24) with at least one
variant allele to subjects with wild-type alleles for each SNP. ABCB1 2766G>T was not evaluated because all subjects were homozygous wild-






Partial AUC from 0–6 h for verifying extrapolated AUC0–12 h.
‡
Weight-adjusted apparent oral clearance.
§
Correlation analysis was performed using *1B/*1B versus *1/*1B and *1/*1 as only one subject was *1/*1.
AUC: Area under the concentration time curve; CL/F: Apparent oral clearance; NVP: Nevirapine.
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Table 3
Multiple variable model determination.
Covariates p-value Model




ABCB1 3435C>T 0.6735 N
NR1I2 44477T>C 0.8535 N
NR1I2 63396C>T 0.3883 N





N: Excluded from model; Y: Included in model.
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